Settled
Do GIP/GLP-1 & amylin agonists improve body weight & composition more than other treatments?
Mostly studied in obesity & overweight. Also asked versus placebo.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Very likely. So far, established.
NoUnsureYes
- Belief
- 1.00 (range 0.90–1.00)
- Trials for
- 8
- Trials against
- 0
- Inconclusive
- 0
Already under way
- Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity: A Placebo-Matched Randomised Controlled TrialNCT06180616 · not yet recruiting · started 2026
- A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Oral NA-931, Alone or in Addition to Open Label Subcutaneous Tirzepatide , to Investigate…NCT06732245 · not yet recruiting · started 2026
- The Effects of Tirzepatide Use on Muscle and Vascular Function Among Obese Older AdultsNCT06811324 · recruiting · started 2026
- A Pre-Operative Window Study of Tirzepatide in Obesity-Driven Endometrial CancerNCT07065552 · recruiting · started 2026
- Safety and Effectiveness of Tirzepatide(Spartina )in Chronic Kidney Failure a Single-center StudyNCT07176663 · not yet recruiting · started 2026
The evidence so far
- Registered trials
- 165
- With posted results
- 31
- Published papers
- 25
Of 231 decided analyses: 213 favor gip/glp-1 & amylin agonists, 14 find no difference, 4 favor the comparator.
Papers
- Efficacy and safety of once-weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT-2 trial.Trial report · 2025
- A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes.Trial report · 2022
- Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis.Meta-analysis / systematic review · 2025
- Head-to-head comparison of tirzepatide and semaglutide for weight loss: A systematic review and meta-analysis.Meta-analysis / systematic review
- Tirzepatide for adults living with obesity.Meta-analysis / systematic review · 2025
- The efficacy and safety of dual GIP/GLP1 receptor agonists (tirzepatide) in diabetes and obesity: a systematic review and network meta-analysis.Meta-analysis / systematic review · 2026
Trials
- Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)NCT04184622 · 34 posted results
- Efficacy and Safety of Once-Weekly Tirzepatide in Participants With Obesity Disease: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-J)NCT04844918 · 22 posted results
- Efficacy and Safety of Tirzepatide Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-CN)NCT05024032 · 21 posted results
- Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)NCT04657003 · 18 posted results
- A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Tirzepatide Monotherapy Compared With Placebo in Chinese Participants With Type 2 DiabetesNCT05963022 · 15 posted results
- Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)NCT04660643 · 17 posted results
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With an Open-Label Extension Assessing the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of Tirzepatide in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, or Basal Insulin, or BothNCT05260021 · 12 posted results
- A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes MellitusNCT03131687 · 16 posted results